Acurx Pharmaceuticals’ (ACXP) Buy Rating Reiterated at HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Stock Down 3.4%

ACXP traded down $0.05 during trading on Tuesday, reaching $1.30. 101,440 shares of the company’s stock were exchanged, compared to its average volume of 1,111,874. Acurx Pharmaceuticals has a fifty-two week low of $1.27 and a fifty-two week high of $8.34. The business has a 50 day moving average price of $1.43 and a 200 day moving average price of $2.08. The company has a market capitalization of $7.20 million, a P/E ratio of -0.48 and a beta of -2.02.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). As a group, research analysts forecast that Acurx Pharmaceuticals will post -2 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.